Invion Limited

A clinical-stage drug development company focused on the development of treatments for major market opportunities in inflammatory diseases including asthma, chronic bronchitis and lupus. Hear CMO Dr Mitchell Glass discuss Invion's recent data from Invion's asthma and COPD programs.

Investor Presentation

Invion has two phase II drug candidates: INV102 (nadolol) – a beta blocker being repurposed to treat inflammatory airway diseases; and INV103 (ala-Cpn10) – a modified human protein targeted to treat inflammation caused by autoimmune disease. Read more in the latest corporate presentation